ACITRETIN Drug Patent Profile
✉ Email this page to a colleague
When do Acitretin patents expire, and what generic alternatives are available?
Acitretin is a drug marketed by Barr Labs Inc, Impax Labs Inc, Mylan, Sigmapharm Labs Llc, and Teva Pharms Usa. and is included in six NDAs.
The generic ingredient in ACITRETIN is acitretin. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the acitretin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Acitretin
A generic version of ACITRETIN was approved as acitretin by BARR LABS INC on April 4th, 2013.
Summary for ACITRETIN
| US Patents: | 0 |
| Applicants: | 5 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 119 |
| Clinical Trials: | 37 |
| Patent Applications: | 5,768 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ACITRETIN |
| What excipients (inactive ingredients) are in ACITRETIN? | ACITRETIN excipients list |
| DailyMed Link: | ACITRETIN at DailyMed |
Recent Clinical Trials for ACITRETIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Singapore General Hospital | Phase 4 |
| Translational Immunology Institute | Phase 4 |
| South Valley University | Phase 4 |
Pharmacology for ACITRETIN
| Drug Class | Retinoid |
Medical Subject Heading (MeSH) Categories for ACITRETIN
Anatomical Therapeutic Chemical (ATC) Classes for ACITRETIN
US Patents and Regulatory Information for ACITRETIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr Labs Inc | ACITRETIN | acitretin | CAPSULE;ORAL | 091455-001 | Apr 4, 2013 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Mylan | ACITRETIN | acitretin | CAPSULE;ORAL | 202148-001 | Sep 10, 2015 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Impax Labs Inc | ACITRETIN | acitretin | CAPSULE;ORAL | 202552-002 | Dec 23, 2015 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Sigmapharm Labs Llc | ACITRETIN | acitretin | CAPSULE;ORAL | 204633-002 | May 22, 2015 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Mylan | ACITRETIN | acitretin | CAPSULE;ORAL | 203707-001 | Sep 10, 2015 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva Pharms Usa | ACITRETIN | acitretin | CAPSULE;ORAL | 202897-002 | Apr 4, 2013 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
